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Abstract
Background: Multiple sclerosis (MS) is associated with pathogenic autoimmunity primarily focused on major CNS-
myelin target antigens including myelin basic protein (MBP), proteolipidprotein (PLP), myelin oligodendrocyte
protein (MOG). MS is a complex trait whereby the HLA genes, particularly class-II genes of HLA-DR15 haplotype,
dominate the genetic contribution to disease-risk. Due to strong linkage disequilibrium in HLA-II region, it has been
hard to establish precisely whether the functionally relevant effect derives from the DRB1*1501, DQA1*0102-
DQB1*0602, or DRB5*0101 loci of HLA-DR15 haplotype, their combinations, or their epistatic interactions.
Nevertheless, most genetic studies have indicated DRB1*1501 as a primary risk factor in MS. Here, we used ‘HLA-
humanized’ mice to discern the potential relative contribution of DRB1*1501 and DQB1*0602 alleles to
susceptibility to “humanized” MS-like disease induced by PLP, one of the most prominent and encephalitogenic
target-antigens implicated in human MS.
Methods: The HLA-DRB1*1501- and HLA-DQB1*0602-Tg mice (MHC-II
-/-), and control non-HLA-DR15-relevant-Tg
mice were immunized with a set of overlapping PLP peptides or with recombinant soluble PLP for induction of
“humanized” MS-like disease, as well as for ex-vivo analysis of immunogenic/immunodominant HLA-restricted T-cell
epitopes and associated cytokine secretion profile.
Results: PLP autoimmunity in both HLA-DR15-Tg mice was focused on 139-151 and 175-194 epitopes. Strikingly,
however, the HLA-DRB1*1501-transgenics were refractory to disease induction by any of the overlapping PLP
peptides, while HLA-DQB1*0602 transgenics were susceptible to disease induction by PLP139-151 and PLP175-194
peptides. Although both transgenics responded to both peptides, the PLP139-151- and PLP175-194-reactive T-cells
were directed to Th1/Th17 phenotype in DQB1*0602-Tg mice and towards Th2 in DRB1*1501-Tg mice.
Conclusions: While genome studies map a strong MS susceptibility effect to the region of DRB1*1501, our
findings offer a rationale for potential involvement of pathogenic DQ6-associated autoimmunity in MS. Moreover,
that DQB1*0602, but not DRB1*1501, determines disease-susceptibility to PLP in HLA-transgenics, suggests a
potential differential, functional role for DQB1*0602 as a predisposing allele in MS. This, together with previously
demonstrated disease-susceptibility to MBP and MOG in DRB1*1501-transgenics, also suggests a differential role for
DRB1*1501 and DQB1*0602 depending on target antigen and imply a potential complex ‘genotype/target antigen/
phenotype’ relationship in MS heterogeneity.
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Multiple sclerosis (MS) is a disease of the human central
nervous system (CNS), characterized by perivascular
inflammation, accompanied by primary demyelination
and axonal damage. It is believed to result from autoim-
mune mechanisms leading to destruction of myelin, pre-
sumably initiated by abnormally activated T cells that
recognize CNS components in MS patients. The patho-
genic autoimmunity in MS appears to be associated
with complex immune reactivity directed against several
CNS-specific and non CNS-specific components [1,2].
Many of the primary target antigens detected in T cell
responses of MS patients share identity with those CNS
antigens demonstrated to cause overt, clinical EAE in
laboratory animals. Thus far, several myelin proteins,
myelin basic protein (MBP), proteolipid protein (PLP),
and more recently, myelin oligodendrocyte glycoprotein
(MOG), myelin-oligodendrocytic basic protein (MOBP),
oligodendrocye specific protein (OSP) [1,2], and the
neuronal components [(b-synuclein (bSyn), neurofila-
ment light (NF-L)] [3,4] fulfill these criteria. In attempts
to establish a molecular etiology of MS that both
explains the genetic associations and potentiates specific
therapeutic interventions, defining the potentially patho-
genic epitopes of major MS-related CNS target antigens,
in the context of their HLA restricting genes/alleles, and
characterization of the corresponding responder T cells
will be essential.
Both genetic and environmental factors have been
shown to contribute to the pathogenesis of MS. Despite
extensive studies on the role of genetic and environmen-
tal factors that have been associated with the etiology of
MS [2], the effects of other potential MS-risk factors are
dwarfed by the contribution from the HLA class II
region [5-8]. In recent genome-wide association studies,
several HLA and non-HLA genes have been associated
with the disease, with the HLA-class II genes, particu-
larly those of the HLA-DR15 haplotype (HLA-
DQB1*0602- HLA-DQA1*0102; HLA-DRB1*1501; HLA-
DRB5*0101) bearing the strongest association to MS
[9,10]. The HLA DR15 haplotype, which is most preva-
lent among Caucasian MS patients, encodes three func-
tional class II heterodimers, DR15 (the DRA1*0101/
DRB1*1501 pair), DRB5 (the DRA1*0101/DRB5*0101
pair), and DQ6 (DQA1*0102/DQB1*0602 pair). Due to
extensive linkage disequilibrium across the HLA-II
region [11], fine-genetic mapping studies could not
unequivocally establish whether the functionally relevant
effect on MS derives from DRB1*1501, DQA1*0102,
DQB1*0602, or DRB5*0101 loci of HLA-DR15, their co-
expression, or from their epistatic interactions [7,12].
Candidate gene association studies for HLA association
in MS tend to indicate DRB1*1501 (with the
DQB1*0602 allele in linkage disequilibrium) as the pri-
mary risk factor for increased susceptibility [13-15].
Relatively few studies, often in smaller defined ethnic
groups, indicate an effect of DQB1*0602 independent of
DRB1*1501 [16,17], or of DRB1*1501 independent of
DQB1*0602 [18]. In functional, in vitro studies of T-cell
clones and lines from MS patients, emphasis has been
largely on DR15-restricted T cells specific for various
myelin components, particularly MBP [19,20]. There
have been rare studies of HLA-DQ6-restricted T cells
clones in MS patients, including cells specific for MBP
85-99 [21,22]. The relative dominance of HLA-DR in
these functional studies may relate to the fact that
HLA-DR is more strongly expressed by peripheral anti-
gen presenting cells [23]. However, HLA-DQ shows a
distinctive pattern of thymic expression, and has been
posited to exert an effect through thymic selection [23].
HLA-Tg mice constitute a valuable resource for dis-
secting the association of disease susceptibility with the
specific gene products of the HLA-DR15 haplotype. Stu-
dies with HLA class-II Tg mice have demonstrated
HLA-DR-dependent disease following immunization by
MBP, PLP, or MOG [24-27]. In HLA class-II Tg mice
expressing the DRB1*1501 allele of the HLA-DR15 hap-
lotype, the susceptibility t oE A Ei n d u c e db yM B P[ 2 4 ]
or MOG [27] supports a functional contribution of
DRB1*1501 to MS. However, our recent studies in
HLA-DR15-Tg mice (DRB1*1501, DQB1*0602) show
that susceptibility to MOBP is determined by HLA-
DQB1*0602, and not by the DRB1*1501 product of the
HLA-DR15 haplotype [28]. These studies were the first
to functionally implicate DQ6-associated autoimmunity
in the pathogenesis of MS and to offer a mechanism for
DQB1*0602 as a disease-predisposing allele, in contrast
to some human and transgenic mouse studies suggesting
a protective role for HLA-DQ6 [29-31].
While our recent study [28] showing that MOBP can
induce MS-like disease in HLA-DQB1*0602-Tg mice
offers a rationale for the HLA-DQB1*0602 association
with MS, it raises the question of whether DQ6-autoim-
munity against other myelin/neuronal target antigens/
epitopes can be pathogenic and may also play a role in
pathogenesis of MS. PLP autoimmunity has been
strongly implicated in some functional studies attempt-
ing to correlate immune reactivity with MS relapse [32].
We therefore investigated the pathogenic potential of
PLP in HLA-Tg mice expressing the DRB1*1501 and
DQB1*0602 gene products of the HLA-DR15 haplotype.
We show that, rather strikingly, the disease-susceptibility
to the one of the most prominent encephalitogenic tar-
get antigen implicated in human MS, is determined by
DQB1*0602, and not by DRB1*1501. These findings sug-
gest a mechanism for the involvement of HLA-
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pathogenesis of MS, implicating the HLA-DQB1*0602 in
the genetic susceptibility to MS.
Methods
Mice
HLA-DR15 (DRA1*0101;DRB1*1501) and control
(DRA1*0101; DRB1*1502)-Tg mice (MHC-II
-/-) (referred
to here as DRB1*1501-Tg and DRB1*1502-Tg, respec-
tively) were generated by Dr. Chella David [29]. The
HLA-DQ6 (DQA1*0102;DQB1*0602)-Tg mice (MHC-
II
-/-) (referred to here as DQB1*0602-Tg), were gener-
ated by Dr. Danny Altmann as described previously
[33]. HLA-DQ6 transgenic mice were crossed to an H-
2Ab
-/- line [34] and maintained thereafter as homozy-
gous knockouts for H-2Ab. The expression level of
HLA-DRB1*1501 and HLA-DQB1*0602 heterodimers
on peripheral B cells from DRB1*1501- and
DQB1*0602-Tg mice, respectively, was as previously
shown by us [28]. Both DRB1*1501-Tg and DQB1*0602-
Tg (and also control DRB1*1502-Tg) mice were main-
tained as homozygous lines at The Weizmann Institute
SPF animal facility. All animal procedures and experi-
m e n t sw e r ea p p r o v e db yt h eI A C U Ca tT h eW e i z m a n n
Institute
Recombinant human ΔPLP and PLP synthetic peptides
ΔPLP was constructed to delete the sequences encompass-
ing the hydrophobic putative transmembrane domains of
the human PLP (Figure 1A&1B), thus enabling the expres-
sion of soluble protein. The ΔPLP was synthetically con-
structed using overlapping oligomers (depicted in Figure
1A) spanning the whole DNA sequence encoding the
ΔPLP (Figure 1B). 50- to 70-nucleotide-long oligonucleo-
tides, which represent codons of the amino acid residues
of the aligned ΔPLP, and which are complementary at
their 5’ and/or 3’ ends to their neighboring oligonucleo-
tides by an overlap of 15-18 nucleotides were synthesized
by the Weizmann Institute of Science Synthesis Unit.
Relevant oligonucleotides include specific restriction endo-
nuclease sites to enable cloning (or in-frame ligation of
internal DNA fragment if necessary). The following oligo-
nucleotides - (1) 5’ATGGAATTCGCTAGCATGGGCT
TGTTAGAGTGCTGTGCAAGATCACTGGTAGGA-
CATGAAGCC 3’;(2) (rev) 5’ GTTTTTCGAGAAA-
TAGGTCTCAATTAACTTTTCTGTGCCAGTGAGG
GCTTCATGTCCTACCAG 3’;( 3 )5 ’ ACCTATTTCTC-
GAAAAACTACCAAGACTATGAGTATCTCATCAAT
GTGGCTGAGGGCTTCTAC 3’;( 4 )( r e v )5 ’ GCCAAA-
GATCTGACGGACTGCGCCGGTGGTGTAGAAGC
CCTCAGCCAC 3’;( 5 )5 ’ CAGTCCGTCAGATCTTTG
GCGACTACAAGACCACCATCAGCGGCAAGGGCCT-
GAGCGCAACGGTA 3’;( 6 )( r e v )5 ’ AGCTTGATGTT
GGCCTCTGGAACCCCTCCCCTTCTGGCCCCCTGT-
TACCGTTGCGCTCAGGCC 3’;( 7 )5 ’ AGAGGCCAA-
CATCAAGCTCATTCTTTGGAGCGTGTGTGTCAT
TGTTTGGGAAAATGGCTGGGA 3’;( 8 )( r e v )5 ’ GGT
GGTCCAGGTGTTGAAGTAAATGCCCACAAACTTG
TCTGGATGTCCCAGCCATTTTCCCAA 3’;( 9 )5 ’
TTCAACACCTGGACCACCAGCCAGTCTATTGCC
TTCCCAAGCAAGACCTCGGCCAGTATAGGC 3’; (10)
A.
C.
MW    1       2       3      4  
  90
117
 49
 34
 25
 19
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242    262  
14a
276  12      34 64     86 1 154      173 6     86 6 64     4      17
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

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Figure 1 Preparation of recombinant hΔPLP.( A) Scheme for the
preparation and amplification of the synthetic hΔPLP DNA template,
which is devoid of the hydrophobic putative transmembrane
domains of hPLP, represented by the upper triangles, using the PCR
overlap extension technique. (B) Alignment of deduced amino acid
sequence of hΔPLP with full length native human PLP. The hΔPLP
amino acid sequence derived from the DNA sequence of the
pRSET/hΔPLP. The dot line in the hΔPLP sequence indicates the
positions of the deleted hydrophobic domains. Underlined C and S
represent the cysteine to serine substitutions introduced to
minimizing incorrect refolding and to increase solubility of the
expressed protein. (C) Coomassie Brilliant Blue-stained gel of the
expressed and purified hΔPLP from bacteria; lane 1, bacterial host
proteins before IPTG induction (20 μg of cellular proteins); lane 2,
bacterial proteins after IPTG induction (20 μg cellular proteins; lane
3, hΔPLP (~1.5 μg) purified by metal chelate affinity
chromatography on Ni
2+-nitrilotriacetic acid agarose.
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TGGCGTCAGCAGAGAGACTGCCTATACTGGCC-
GAGGT 3’; (11) 5’ GGTGTTCTCCCATGGAATGCTTT
CCCGGGCAAGGTTTCTGGCTCCAACCTTCTGTC-
CATCAGC 3’; (12) (rev) 5’ GTTAGCAATAAACA
GGTGGAAGGTCATTTGGAACTCAGCTGTTTTGCT-
GATGGACAGAAGGTT 3’;( 1 3 )5 ’ CACCTGTTTAT
TGCTAACTTTGCCGTCCTTAAACTCATGGGCCGT
GGCACCAAGTTCCTC 3’;( 1 4 )( r e v )5 ’ TCAGGATCCT-
CACTCGAGGAACTTGGTGCC, 3’; - were used in PCR
extension for the synthesis of the ΔPLP template (Figure
1A). The template was amplified by PCR using the (1a) 5’
ATGGAATTCGCTAGCATGGGCTTGTTA 3’; (14)
5’TCAGGATCCTCACTCGAGGAACTTGGTGCC3’ pri-
mers, in which NheI and BamHI restriction sites, respec-
tively, are included. The template synthesis, PCR
amplification and cloning of the DNA coding the ΔPLP
were carried out as we previously described [35]. The PCR
product was cloned into pGEM-T vector (Promega, Madi-
son, WI, USA) was than subcloned into pRSET bacterial
expression vector (Invitrogen, San DIEGO, CA, USA) 3’ to
its 6xHis tag, and sequenced using pRSET specific primers
and ΔPLP-specific internal primers to confirm an open
reading frame for a fusion protein with the amino acid
sequence shown in Figure 1B, preceded by (Met)-Arg-Gly-
Ser-(His)6-Gly-Met-Ala-Ser. Expression in E. coli and pur-
ification of ΔPLP on Ni2+-NTA agarose was carried out
as detailed previously by Kerlero de Rosbo et al. [36].
The synthetic overlapping peptides spanning ΔPLP
and their amino acid sequence are listed in Table 1. All
peptides (at least 80% purity) were synthesized in the
laboratory of Prof. M. Fridkin, Department of Organic
Chemistry, The Weizmann Institute of Science, using
the Fmoc technique with an automated peptide synthe-
sizer (AMS422; Abimed, Langenfeld, Germany).
Induction of EAE
Mice were injected subcutaneously at one site in the
flank with 200 μl of emulsion containing 200 μg ΔPLP
or 200 μg peptide in CFA with 300 μg Mycobacterium
tuberculosis H37Ra (Mt.) (Cat. No: 3114-25, Difco
Laboratories, Detroit, MI). Mice received 300 ng pertus-
sis toxin (Cat. no. P-9452, Sigma, Saint-Louis, MI) in
500 μl PBS in the tail vein immediately and 48 h after
the immunization (Protocol 1). In some cases, as indi-
cated, mice received an identical booster immunization
on the flank, one week later (Protocol 2). Following the
encephalitogenic challenge, mice were observed daily
and clinical manifestations of EAE were scored on a
scale of 0-6: 0, no clinical signs; 1, loss of tail tonicity; 2,
flaccid tail; 3, hind leg paralysis; 4, hind leg paralysis
with hind body paresis; 5, hind and fore leg paralysis; 6,
moribund, as previously described [37].
T cell responses
Mice were immunized with 150 μg ΔPLP or individual
peptides emulsified in complete Freund’sa d j u v a n t
(CFA) containing 150 μg Mycobacterium tuberculosis
(Mt) H37Ra (Cat. No:3114-25, Difco Laboratories,
Detroit, MI). Ten or 14 days post immunization, drain-
ing lymph nodes or spleens, respectively, were removed
and cultured in triplicate in the presence or absence of
relevant antigens, as previously described [38]. The cul-
tures were incubated for 48-72 h at 37 C in humified air
containing 7.5% CO2.[
3H] Thymidine (1 mCi/well) was
added for an additional 16 h of incubation and the cul-
tures were then harvested and counted using a Matrix
96 Direct Beta Counter (Packard Instrument, Meriden,
CT). The results were expressed as stimulation index
(SI; mean cpm of antigen containing cultures/mean c.p.
m of medium-containing cultures). In some experi-
ments, as indicated, mice were immunized as for induc-
tion of EAE (Protocol 2).
Cytokine analysis
IL-2, IFN-g, IL-4, IL-10 and TNF-a were measured by
ELISA according to standard protocols from PharMin-
gen (San Diego, CA), as described previously [39]. The
capture antibodies were rat anti-mouse IL-4 (18191D;
PharMingen), rat anti-mouse IL-2 (18161D; PharMin-
gen), rat anti-mouse IL-10 (AMC0102; BioSource Inter-
national, Camarillo, CA,) rat anti-mouse IFN-g
(AMC4834; BioSource International), and rat anti TNF-
a (555052;. PharMingen) The biotinylated antibodies
used were rat anti-mouse IL-4 (18042D), rat anti-mouse
IL-2 (18172D), rat anti-mouse IL-10 (18152D) and rat
Table 1 List of the synthetic peptides spanning hPLP
used in this study
Overlapping human pPLP* Sequence
1-20 GLLECCARCLVGAPFASLVA
30-51 LFCGCGHEALTGTEKLIETYFS
41-60 GTEKLIETYFSKNYQDYEYL
84-102 LLLAEGFYTTGAVRQIFGD
95-116 AVRQIFGDYKTTICGKGLSATV
107-124 ICGKGLSATVTGGQKGRG
117-139 TGGQKGRGSRGQHQAHSLERVCH
139-151 HCLGKWLGHPDKF
175-194 IYFNTWTTCQSIAFPSKTSA
175-183S-194 IYFNTWTTSQSIAFPSKTSA
185-206 SIAFPSKTSASIGSLCADARMY
195-216 SIGSLCADARMYGVLPWNAFPG
206-226 YGVLPWNAFPGKVCGSNLLSI
215-235 PGKVCGSNLLSICKTAEFQMT
226-245 ICKTAEFQMTFHLFIAAFVG
257-276 MIAATYNFAVLKLMGRGTKF
*, Peptide sequences correspond to native hPLP, except 175-183S-194
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tin anti mouse TNF-a (B121372; Biolegend). IL-17 was
measured by ELISA using a DuoSet ELISA Development
kit (DY421; R&D Systems, Inc., Minneapolis, MN).
TGF-b was measured by ELISA according to the stan-
dard protocol from R&D Systems (Minneapolis, MN),
using recombinant human TGF-b sRII/Fc chimera as
capture reagent (341-BR; R&D Systems) and biotinylated
anti-human TGF-b1 antibody (BAF240; R&D Systems).
Recombinant human TGF-b1 (240-B; R&D Systems)
was used to construct the standard curve.
Pathological examination
Mice were perfused with 4% paraformaldehyde in PBS,
and the tissues were post-fixed for 24 h at 4°C. Histolo-
gical evaluation was performed on paraffin-embedded
sections of spinal cords that were sampled 19 days post-
immunization as the experiment was terminated. Paraf-
fin sections were stained with H&E and Luxol fast blue
to assess inflammation and demyelination respectively.
In consecutive sections, immunohistochemistry was per-
formed with Abs directed against the following targets:
macrophages/activated microglia (MAC3: BD Pharmin-
gen; Iba-1: Wako-chem, Japan), and T cells (CD3: Che-
micon International) [36]. For staining, paraffin sections
were pretreated with a steamer for 60 min. Bound pri-
mary Ab was detected with a biotin-avidin technique as
previously described in detail [36].
Results
Immunogenic T cell epitopes of hΔPLP in transgenic mice
expressing MS-associated DRB1*1501 and DQB1*0602
products of the HLA-DR15 haplotype
To define HLA-DR15 haplotype-related immunogenic
epitopes of human PLP, DRB1*1501- and DQB1*0602-Tg
mice were immunized with each of the individual over-
lapping peptides spanning the aqueous-soluble recombi-
nant hΔPLP [Δ, deleted of hydrophobic (transmembrane)
domains] (listed in Table 1). Ten days later, the primed
LNC were analyzed ex-vivo for a recall proliferative
response to variable concentrations of the immunizing
peptide. As shown in Figure 2A, the phPLP30-51, 139-
151, 175-194, 185-206, and 206-226 peptides that elicit a
significant T-cell response in DRB1*1501-Tg mice are
likely to contain DRB1*1501-presented immunogenic
eitopes, with phPLP175-194, 185-206, and 206-226 elicit-
ing the strongest DRB1*1501-associated T-cell response.
In the DQB1*0602-Tg mice, T-cell responses were seen
in response to peptides phPLP30-51, 139-151, 175-194,
215-235, and 257-276 (Figure 2B), with responses to
phPLP30-51, 139-151, 175-194, and 257-276 being about
equally strong, although the responses to phPLP30-51
and phPLP257-276 were larger.
As a control for the DRB1*1501-Tg mice, we mapped
the hΔPLP T-cell epitopes also in DRB1*1502-Tg mice,
which differ from HLA-DRB1*1501 only in one amino
acid residue [glycine for leucine substitution at position
86 [40]]. This DR15 allele is the predominant one in SE
Asia and is rarely associated with MS. As shown in Fig-
ure 2C, the immunodominant epitope profile in
DRB1*1502-Tg mice differed from that in DRB1*1501-
Tg mice. Thus peptides PLP185-206, 206-226, and 226-
245 were co-dominant in DRB1*1502-Tg mice, while
PLP30-51, 139-151,175-194 epitopes that were immuno-
genic in DRB1*1501-Tg mice could not elicit T cell
responses in DRB1*1502-Tg mice, suggesting the
Figure 2 Mapping immunogenic DR15- and DQ6-associated
PLP T-cell epitopes by immunization with individual
overlapping peptides spanning hΔPLP. HLA-DRB1*1501-Tg, HLA-
DQB1*0602-Tg and HLA-DRB1*1502-Tg (as control HLA-Tg line) mice
were immunized (s.c.) each with an individual peptide (derived from
native hPLP) of the overlapping peptides spanning hΔPLP. Ten days
later, the primed LNC of immunized mice were analyzed ex-vivo for
recall proliferative response to the immunizing peptide (0.5 - 5 μg/
ml). Results expressed as stimulation index (S.I., mean cpm of
antigen containing cultures/mean c.p.m of medium-containing
cultures) are from one experiment with pooled draining LNC from
two mice immunized with each individual peptide. Results are
representative of three independent experiments.
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for recognition of PLP epitopes, and the specificity of
our peptide immunization.
Analysis of immunogenic/immunodominant T-cell
epitopes following immunization of DRB1*1501- and
DQB1*0602-Tg mice with hΔPLP
To validate the DR15-haplotype-relevant epitopes that had
been defined by immunization with the individual peptides
and to distinguish which were dominant and which cryp-
tic, we immunized DRB1*1501- and DQB1*0602-Tg mice
with aqueous-soluble recombinant hΔPLP (Figure 1). It
should be noted that in order to increase the water-solubi-
lity of the recombinant hΔPLP, several cysteine residues of
the hΔPLP were replaced by serine (Figure 1B, underlined
cysteine residues). We indeed obtained a highly water-
soluble recombinant hΔPLP, however, some of the
cysteines appeared critical for some T cell epitopes, as
described below. Figure 3A shows that the hΔPLP pre-
paration was immunogenic for the DRB1*1501- and
DQB1*0602-Tg lines, as the mice mounted a significantly
higher specific T cell response to hΔPLP than that to con-
trol non-relevant recombinant protein, recombinant
human MOG (rhMOG), and that the T-cells reactive
against the hΔPLP in DRB1*1501- and DQB1*0602-Tg
mice were CD4
+ and DRB1*1501- or DQB1*0602-
restricted, respectively (Figure 3B). Primed LNCs from
DRB1*1501- and DQB1*0602-Tg mice that were immu-
nized with hΔPLP/CFA, were analyzed ex-vivo for a recall
proliferative response to a panel of overlapping peptides
spanning the hydrophilic domains of native hPLP, at var-
ious concentrations. The results obtained from two inde-
pendent experiments showed that hΔPLP-primed LNCs of
both DRB1*1501- and DQB1*0602-Tg mice reacted to a
single epitope only, the PLP139-151 [(Additional file 1:
Figure S1). i.e., data from these experiments were similar
to the data of Figures 3E&3F without the mutated peptide
PLP175-183S-194].
These results may suggest that PLP139-151 is the
immunodominant epitope of PLP for DRB1*1501- or
DQB1*0602-Tg mice, and all the other immunogenic
epitopes defined by peptide immunization (Figure
2A&2B) are cryptic. However, before drawing a final
conclusion that PLP139-151 is indeed the sole immuno-
dominant epitope of PLP for DRB1*1501- or
DQB1*0602-Tg mice and all the other immunogenic
epitopes defined by peptide immunization (Figure
2 A & 2 B )a r ec r y p t i c ,w eh a v ee x a m i n e dw h e t h e rt h e
replacement of several cysteines by serine in the hΔPLP,
had any effects on the immunogenicity of epitopes, as
the cysteines in the synthetic overlapping peptides were
left intact. Thus, the inability of immunogenic phPLP30-
51, 41-60, and 195-216 (Figure 2A), which did not con-
tain cysteine or their corresponding cysteines in hΔPLP
were left intact, to stimulate hΔPLP-primed T-cells
from DRB1*1501-Tg mice argues that these peptides
indeed contain cryptic PLP epitopes for DRB1*1501-Tg
mice. Similarly, immunogenic phPLP30-51, 215-235, and
257-276 peptides (Figure 2B), for which their corre-
sponding cysteines in hΔPLP were not replaced to ser-
ine, contain cryptic PLP epitopes for DQB1*0602-Tg
mice as they were non-stimulatory to hΔPLP-primed
cells. The question remains as to whether the immuno-
genic phPLP175-194, 185-206 and 206-226 peptides
(Figures 2B&2C) which have a Cys that was replaced by
Ser in hΔPLP and were not stimulatory for hΔPLP-
primed T-cells from DRB1*1501- and/or DQB1*0602-Tg
mice (indicated by an asterisk(s) in Figures 3E&3F) are
also cryptic, or whether the replacement of Cys by Ser
affected their immunogenicity. This question is of parti-
cular significance for phPLP175-194 that was found to
be one of the major encephalitogenic PLP epitopes in
DQB1*0602-Tg mice (Table 2, Figure 4).
To resolve this question, we first used bioinformatic
modeling to predict the nonameric core epitope(s) of
the 175-194 region of human PLP with preferred bind-
ing mode to DRB1*1501 and/or DQB1*0602 molecules.
This modeling [carried out by DR. M. Eisenstein, Che-
mical Research Support Unit, Weizmann Institute, as
previously described for I-A
b/MOG epitopes [38], but
using the known 3D structures of DR15 (PDB -1BX2)
and DQ6 (PDB-1UVQ) molecules] predicted the
PLP178-NTWTTCQSI-186 as core nonameric epitope
of phPLP175-194 for DRB1*1501, and the two overlap-
ping nonameric core epitopes, PLP178-NTWTTCQSI-
186 and PLP179-TWTTCQSIA-187, with preferred
binding mode to the DQB1*0602 molecule. Further-
more, the cysteine (183C) within each of these nona-
meric core epitopes was predicted to be at a critical
MHC (p6 for PLP178-186) or TCR (p5 for PLP179-187)
contact position, suggesting that its replacement by
another residue (183S) is likely to affect immunogeni-
city/antigenicity of the PLP175-194 in DRB1*1501- or
DQB1*0602- Tg mice. This possibility was then con-
firmed experimentally by showing that PLP175-194-
primed LNCs from DRB1*1501- or DQB1*0602-Tg mice
could be stimulated by the native PLP175-194 peptide,
but not by mutated peptide PLP175-183S-194 (Figures
3C&3D). Moreover, ex-vivo analysis of the recall prolif-
erative response of hΔPLP-primed LNCs of both
DRB1*1501- and DQB1*0602-Tg mice to a panel of the
overlapping peptides spanning the hydrophilic domains
of native hPLP, as well as to the mutated peptide
PLP175-183S-194 comprising the 183C > S replacement
in the hΔPLP, showed a significant reactivity against
PLP139-151 and also against mutated PLP175-183S-194
peptide, but not against the native PLP175-194 peptide
(Figures 3E&3F).
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Page 6 of 15Figure 3 Epitope-specificity of hΔPLP -primed T-cells.( A) Immunogenicity of hΔPLP in DRB1*1501- and DQB1*0602-Tg mice. HLA-Tg mice (two
mice per Tg line) were immunized (s.c.) with 200 μgo fh ΔPLP in CFA. LNCs from draining LNs obtained 10 later were analyzed ex-vivo for their
recall proliferative reponse to 5 μg/ml of hΔPLP or to hMOG (as control recombinant protein). Results (S.I.) are from pooled lymphocytes of each
immunized HLA-Tg line. (B) HLA-class II restriction of hΔPLP primed LNCs. DRB1*1501- and DQB1*0602-hΔPLP-primed lymphocytes from (A) were
analyzed in-vitro for their recall prolifrative response to hΔPLP in the absence or presence of blocking mAb specific for mouse CD4 (Leaf
™Purified anti-mouse CD4), CD8 (Leaf™ purified anti-mouse CD8a), or specific for human HLA-DR (L243) or HLA-DQ (L2) class-II molecules, or
respective isotype control Abs.% inhibition - the S.I. calculated for the recall proliferative response in the presence of neutralizing Abs was
divided by the S.I. of the response in the absence of neutralizing Abs (×100). (C, D) Antigenicity of mutated PLP175-194 peptide (PLP175-183S-194).
DRB1*1501 (C) - and DQB1*0602 (D)- Tg mice (two mice/group) were immunized with 200 μg phPLP175-194 in CFA. Cells from draining LNs
obtained 10 days later were analyzed ex-vivo for their recall proliferative response to 1 or 2.5 μg/ml of native phPLP175-194, PLP175-183S-194
mutant peptide, or hΔPLP. The proliferative response was measured as described in Methods. Results (S.I.) are from pooled lymphocytes of
immunized HLA- Tg mice. (E, F) Ex-vivo analysis of immunodominant epitopes. Tg mice (two mice per HLA-Tg line) were immunized with 200 μg
of in CFA at the flank, as described in Methods for the induction of EAE (protocol 2). Spleen cells were obtained from each of the immunized
mice on day 14 after immunization and cultured in vitro in triplicates in the absence or presence of 1 or 2.5 μg/ml of each of the overlapping
peptides (derived from native hPLP) spanning the hΔPLP, and in the presence of PLP175-183S-194 mutant peptide. Results are the mean S.I. of
two individual spleens from mice immunized with same peptide in each HLA-Tg line. Results obtained from another independent experiment
that was carried out in the same manner showed a similar pattern of reactivity to the overlapping peptides. *, and **, represent native PLP
peptides, the cysteines of which were replaced by serine in the hΔPLP, where *, depicts peptides containing Cys within the nonameric core
epitope for DRB1*1501 and/or DQB1*0602 molecule, but is not a major TCR or MHC binding residue, as predicted in silico: and **, depicts
peptides containing Cys in the nonameric core epitope for DRB1*1501 and/or DQB1*0602 molecule that was predicted in silico to be a major
TCR-contact or MHC-contact residue.
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data (Figures 3C-F), suggests that the encephalitogenic
PLP175-194 epitope is unlikely to be cryptic, and that
PLP139-151 and PLP175-194 are the co-dominant epi-
topes of PLP for both DRB1*1501- and DQB1*0602-Tg
mice. These data also suggest that contrary to consen-
sus, the Cys to Ser replacement may not be inert for
immunogenicity/antigenicity of T-cell epitopes.
DQB1*0602- but not DRB1*1501-Tg mice are susceptible
to PLP-induced EAE
The HLA-Tg lines were immunized for induction of
EAE with each of the hPLP peptides that harbor T-cell
epitope for each relevant HLA-Tg line, as defined in
Figure 2, regardless of whether some of them were sug-
gested to contain cryptic epitopes for DRB1*1501-Tg
mice (phPLP30-51, 41-60, and 195-216) or for
DQB1*0602-Tg mice (phPLP30-51, 215-235, and 257-
276) (as detailed above). The results summarized in
Table 2 show that inoculation using two encephalito-
genic protocols (see Methods) with any of the
DRB1*1501-immunogenic peptides did not cause clinical
EAE in DRB1*1501-Tg mice. The phPLP95-116 which
overlaps with phPLP91-110 that was reported to be
encephalitogenic for HLA-DR3 mice [26] was also non-
encephalitogenic in DRB1*1501-Tg mice. In contrast,
the encephalitogenic inoculation with the DQB1*0602-
immunogenic peptides resulted in the development of
overt clinical EAE in DQB1*0602-Tg mice by
phPLP139-151 and phPLP175-194 (Table 2). The clini-
cal course of EAE induced in HLA-DQB1*0602-Tg mice
by phPLP139-151 (Figure 4A) or by phPLP175-194 (Fig-
ure 4B) presented with clinical manifestations typical of
classical EAE with caudo-rostral ascending paralysis that
developed about 2 weeks after immunization. Notably,
the Cys to Ser mutation in PLP175-183S-194 peptide
Table 2 Active EAE induction with hPLP peptides
HLA Tg mice Immunization Incidence Maximal clinical severity Day of onset
DRB1*1501 hPLP30-51 0/4 ––
hPLP30-51* 0/4 ––
hPLP41-60 0/4 ––
hPLP41-60* 0/4 ––
hPLP95-116* 0/4 ––
hPLP139-151* 0/3 ––
hPLP175-194 0/3 ––
hPLP175-194* 0/4 ––
hPLP185-206 0/3 ––
hPLP185-206* 0/9 ––
hPLP195-216 0/3 ––
hPLP195-216* 0/4 ––
hPLP206-226 0/3 ––
hPLP206-226* 0/3 ––
hPLP257-276* 0/3 ––
hΔPLP* 0/4 ––
DQB1*0602 hPLP30-51 0/2 ––
hPLP30-51* 0/4 ––
hPLP84-102 0/2 ––
hPLP139-151* 6/15 1,2,1,1,1,1 13,15,16,13,14,14
hPLP175-194* 5/9 2,3,1,3,1 13,14,15,20, 21
h175-183S-194* 0/5 ––
hPLP206-226 0/3 ––
hPLP206-226* 0/4 ––
hPLP215-235 0/4 ––
hPLP215-235* 0/4 ––
hPLP257-276 0/8 ––
hPLP257-276* 0/4 ––
hΔPLP*, ** 0/8 ––
Mice were injected with 200 μg of PLP peptide or hΔPLP, and received 300 ng PT immediately and after 48 h (protocol 1)
*, Mice received a boost after a week (protocol 2)
**, The Cys to Ser replacements in the hΔPLP abrogated the encephalitogeinc potential of epitopes, as shown here for PLP175-183Cys/Ser-194 mutated peptide
and detailed in Results
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Page 8 of 15abrogated the encephalitogenic potential of phPLP175-
194 in the DQB1*0602 Tg mice (Table 2), explaining in
part the failure of the immunization with whole hΔPLP
(containing Cys to Ser replacements) to induce EAE in
DQB1*0602 Tg mice (Table 2).
Differential cytokine profile of DRB1*1501- and
DQB1*0602-derived PLP139-151- and PLP175-194-reactive
T cells
The finding that phPLP139-151 and phPLP175-194 were
encephalitogenic only in DQB1*0602 but not in
DRB1*1501 Tg mice, despite their ability to stimulate
quantitatively similar T cell responses in both Tg lines
demanded further investigation. We therefore analyzed
the Th1/Th2/Th17 cytokine profiles associated with the
T-cell reactivity to phPLP139-151 and phPLP175-194 by
both Tg lines. The phPLP139-151- and phPLP175-194-
primed LNCs derived from DRB1*1501- or DQB1*0602-
Tg mice were stimulated ex-vivo with the relevant prim-
ing peptide, and cytokines secreted into the supernatants
were analyzed. Figure 5 shows that reactivity against
phPLP139-151 and phPLP175-194 in DQB1*0602-Tg
mice was explicitly pro-inflammatory, with variably high
secretion of IL-2, IFNg,I L - 1 7a n dT N F a by PLP139-
151- or PLP175-194-reactive T-cells, respectively, and
relatively low IL-4 and IL-10. This Th1/Th17 cytokine
profile (Figure 5) correlates with the encephalitogenic
capacity of phPLP139-151 and phPLP175-194 in-
DQB1*0602-Tg mice (Table 2, Figure 4). Moreover, the
consistently lower secretion of IL-17 and IL-2 by
phPLP139-151- compared to phPLP175-194- primed
LNCs derived from DQB1*0602-Tg mice, is consistent
with the lower encephalitogenic potential of phPLP139-
151 compared to phPLP175-194 in DQB1*0602-Tg mice
(Table 2 &Figure 4). In contrast to DQB1*0602-Tg
mice, the cytokine profile of the DRB1*1501-derived
primed LNCs against the relevant priming peptide,
phPLP139-151 or phPLP175-194, was of a more anti-
inflammatory type, with low IL-2, IFNg,T N F a and IL-
17, and with secretion of IL-4 by PLP139-151-reactive
T-cells (Figure 5). Thus, the Th2 phenotype of the
phPLP139-151-reactive T-cells, and the very low
Figure 5 Cytokine secretion profile of phPLP139-151, 175-194, and 257-276-primed LNC derived from immunized DRB1*1501- or
DQB1*0602-Tg mice. HLA-DRB1*1501- and DQB1*0602-Tg mice were immunized by s.c. injection of 150 μg phPLP139-151, phPLP175-194 or
phPLP257-276 (as control) in CFA. Ten days later, draining LNC (pooled from 3 mice) were cultured for 48 h without or with the immunizing
peptide, respectively, and supernatants were analyzed for the secretion of indicated cytokines. Values presented (pg/ml) are after background
(without antigen) cytokines were subtracted. The results represent three experiments done in triplicates, and are the mean cytokine
concentration ± SE.
Figure 4 Clinical course of actively induced in HLA-DQB1*0602
Tg mice. EAE was induced by the indicated PLP peptide in CFA as
described in methods (protocol 2): Pertussis toxin was administered
immediately and 48 h after immunization. The mice received an
identical booster immunization with PLP peptide in CFA on the
flank one week later. I, incidence.
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Page 9 of 15secretion of pro-inflammatory cytokines by phPLP175-
194-reactive T-cells derived from DRB1*1501-Tg mice
may explain the relative resistance of these mice to EAE
induction by phPLP139-151 or by phPLP175-194.
Taken together, these patterns of cytokine secretion
suggest that PLP139-151- and PLP175-194-reactive T-
cells are directed to a Th1/Th17 phenotype in EAE-sus-
ceptible DQB1*0602-Tg mice and are more Th2 in nat-
ure in EAE-resistant DRB1*1501-Tg mice.
Pathology of PLP-induced EAE in HLA-DQ6-Tg mice
We analyzed the histopathology associated with the
development of EAE induced in DQB1*0602-Tg mice by
phPLP175-194, as the more potent encephalitogenic
peptide compared to phPLP139-151. The histopathologi-
cal analysis of the spinal cord, brain and optic nerves
show, gross pathological changes typical of classical
EAE, consistent of inflammation (Figure 6a, d, e),
demyelination (Figure 6b) and axonal loss (Figure 6c).
Inflammatory infiltrates were composed mainly of CD3
positive T-cells (Figure 6Ad, Bd, Cd) and macrophages
(Figure 6Ae, Be, Ce). In addition, profound microglia
activation was seen in affected brain and spinal cord
regions (Figure 6Ae, Be) and optic nerve (Figure 6Ce).
An unusual finding was the profound involvement of
the brain (shown here in the cerebellum and optic
nerves) in comparison to the spinal cord. Generally,
EAE induced by PLP or MOG in wild-type mice, the
disease mainly affects the spinal cord, and with increas-
ing disease severity there is an additional involvement of
CNS region, but a gradient remains with the most
severe lesions in the spinal cord compared to other
regions of the CNS. Pathological analysis of phPLP175-
194-induced EAE in DQ6-Tg mice (Figure 6) shows
severe brain involvement [cerebellum (Figure 6B) and
optic nerves (Figure 6C)] exceeding that of spinal cord
involvement (Figure 6A). Inflammatory infiltrates were
composed mainly of CD3 positive T-cells (Figure 6Ad,
Bd, Cd) and macrophages Figure 6Ae, Be, Ce). In addi-
tion, profound microglia activation was seen in affected
brain and spinal cord regions (Figure 6Ae, Be) and optic
nerve (Figure 6Ce). Inflammation was also associated
with a variably extent of demyelination and acute axonal
i n j u r y( F i g u r e6 a - ci nA - C ) .Goverman and colleagues
[42] have suggested that strong involvement of the cere-
bellum and brainstem is a feature of Th17-driven dis-
ease, which is in line with the high Th17 secretion by
PLP175-194-primed LNC derived from DQB1*0602-Tg
mice (Figure 5).
Discussion
In complex trait genetics in general and, notably the
autoimmune diseases, there is a fast approaching chal-
lenge of how to move from gene-wide association and
fine-mapping studies to functional pathways and thera-
peutics. MS is a case in point: genetic studies identify
H L A - D R B 1 * 1 5 0 1a sap r i m a r yr i s kf a c t o ri nM S ,
although the close genetic proximity of HLA-
DQB1*0602 and strong linkage disequilibrium between
the two make it almost impossible to distinguish the
contribution of these genes except through functional
studies. Most functional studies relating to HLA pro-
ducts in MS have focused on DRB1*1501, with little
consideration for the potential contribution of
DQB1*0602-associated autoimmunity to pathogenesis.
Our recent studies in HLA-DR15-Tg mice showing that
susceptibility to MOBP-induced EAE is determined by
HLA-DQB1*0602, and not by DRB1*1501 [28], were the
first to implicate DQB1*0602-associated autoimmunity
in the pathogenesis of MS and to suggest DQ6 as an
important disease predisposing, rather than just a dis-
ease-modifying allele, as previously suggested [30]. We
Figure 6 Histopathology of PLP-induced EAE in HLA
DQB1*0602 Tg mouse. Samples were taken on day19 after
immunization. Panel (A) shows the spinal cord, (B) the cerebellum
and (C) the optic nerve. The sections were stained with hematoxylin
& eosin (a), Luxol fast blue for myelin. (b) Bieschowsky silver
impregnation for axons (c) and by immunocytochemistry for CD3
(d), and Mac-3 (e). Note the unusually profound inflammation in the
cortex and optic nerve. Original magnifications: A and B: × 25; C: ×
100.
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autoimmunity against MOBP is not a limited case, and
that DQB1*0602-autoimmunity against other CNS anti-
g e n sm a ya l s op l a yar o l ei np a t h o g e n e s i so fM S .W e
show that disease-susceptibility to PLP, a highly ence-
phalitogenic protein and one of the most prominent and
‘MS-implicated’ antigens in the CNS, is also determined
by DQB1*0602, and not by DRB1*1501 gene products of
the HLA-DR15 haplotype. Thus, HLA-DRB1*1501
transgenics were found to be refractory to PLP disease
induction, whereas the HLA-DQB1*0602 transgenics
were susceptible, via T-cells reactive against PLP139-151
and PLP175-194 encephalitogenic epitopes. These find-
ings have important bearing on the candidacy of the
DQB1*0602 allele as genetic risk factor for MS.
Analysis of the T-cell autoimmunity against PLP,
which showed that PLP is immunogenic for HLA-
DRB1*1501- and HLA-DQB1*0602-Tg mice also
revealed that the T-cell autoimmunity against PLP in
both transgenics is predominantly directed against
PLP139-151 and PLP175-194 epitopes, which are the
immunodominant and encephalitogenic epitopes for
SJL/J mice [43]. However, although both transgenics
could mount CD4+ T-cells reactive against these co-
dominant PLP epitopes, the PLP139-151 and PLP175-
194-reactive T-cells that developed in DQB1*0602-Tg
mice were of pathogenic Th1/Th17-type cells that
caused the development of clinical EAE in DQB1*0602-
Tg mice, while the PLP139-151 and PLP175-194-reac-
t i v eT - c e l l sw e r eo fam o r eT h 2 - t y p et h a tc o n f e r r e d
resistance to PLP-EAE in DRB1*1501-Tg mice. Further
investigation is required to understand how recognition
of the same epitopes in the context of DQB1*0602
class-II molecule drives Th1/Th17 pathogenic T-cell
autoimmunity, while the recognition of same epitopes
in the context of DRB1*1501 class-II molecule drives
more Th2 type autoimmunity. These findings in the
reductionist transgenic models are quite challenging
since both DRB1*1501 and DQB1*0602 molecules are
co-expressed in HLA-DR15+ MS patients, raising the
question on whether the net T-cell autoimmunity
against PLP, and particularly against the PLP139-151
and PLP175-194 epitopes, in HLA-DR15+ MS would be
of Th1/Th17 pathogenic autoimmunity or more of anti-
inflammatory Th2 type. This question can be resolved
by analyzing the Th1/Th17/Th2-type of T-cell reactivity
against PLP, particularly against PLP139-151 and
PLP175-194 epitopes by PBLs of HLA-DR15+ MS
patients, compared to the Th1/Th17/Th2-type response
by their DRB1*1501- and DQB1*0602-restricted T-cells
reactive against these epitopes. In this context, however,
it is worth mentioning that (DRB1*1501 × DQB1*0602)
F1 double Tg mice, expressing both DRB1*1501 and
DQB1*0602 molecules were recently found to be
resistant to EAE induction by either PLP139-151 or
PLP175-194 epitope (Kaushansky et al., unpublished
data). Why and by what mechanisms the susceptibility
to EAE induced by these immunodominant epitopes
was not inherited in the F1 double-Tg mice as a domi-
nant trait, as is usually the case for EAE susceptibility
to other encephalitogenic antigens/epitopes in labora-
tory animals, is now under investigation in our
laboratory.
The central question of whether HLA-DRB1*1501,
HLA-DQB1*0602, or their co-expression is the primary
risk factor in MS has not been fully resolved by genetic
studies due to their linkage disequilibrium. Although
most MS genetics studies in Caucasian populations sug-
gest HLA-DRB1*1501 as the genetic risk factor in MS
[13-15], several other genetic studies in unique popula-
tions suggest that HLA-DQ alleles may also be a risk
factor. In a small cohort of Norwegian MS patients,
some patients were identified who carried DQB1*0602
or DQB1*0603 without DRB1*1501, but none who were
DRB1*1501 without DQB1*0602 [17]. Related observa-
tions were made in a relatively small sample of Hong
Kong Chinese patients with MS. In that population,
DR15 is expressed without DQB1*0602 and DQB1*0602
without DR15, so that one can ask whether either or
both of the dissociated genes appear to confer an
enhanced risk. It was found that the enhanced risk was
associated with DQB1*0602 [16]. A similar case has
been made for susceptibility in Afro-Brazilians, where
the frequency of DQB1*0602 among patients is higher
than that for the main DR15 allele, DRB1*1503, in that
unique population [44]. A caveat here is the analysis of
HLA-DR and -DQ associations conducted in a large
cohort of African American MS patients, which showed
a selective association with HLA-DRB1*1501 and not
with HLA-DQB1*0602 was identified [18]. Thus, while
primacy of HLA-DRB1*15 or HLA-DQB1*0602 has not
been conclusive in the African populations that show
greater haplotypic diversity than Europeans and distinct
patterns of linkage disequilibrium, a potential contribu-
tion of HLA-DQB1*0602 to MS susceptibility could still
be inferred. The possibility that both HLA-DRB1*1501
and HLA-DQB1*0602 loci influence susceptibility to MS
through epistatic interactions has been demonstrated in
Canadian MS cohorts, where the HLA-DQA1*0102,
which showed no independent association, was found to
interact strongly with HLA-DRB1*1501 in trans, increas-
ing MS risk in the presence of HLA-DRB1*1501 and
playing a protective role in its absence [45]. Nonetheless,
our data showing pathogenic DQB1*0602-associated
autoimmunity against MOBP in HLA-Tg mice [28] and
against PLP (this study) offer a rationale and potential
mechanisms for the HLA-DQB1*0602 association with
MS.
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separating HLA-DR and HLA-DQ, offers a chance to
dissociate these presentation experiments in a genetic
setup rarely seen in humans because of the rarity of
recombination events between these loci. Studies with
HLA class-II Tg mice have previously demonstrated
HLA-DR-dependent disease induced by MBP, PLP, and
MOG [24-27]. However, while susceptibility to MBP-
and MOG-induced EAE in HLA-Tg mice was deter-
mined by the DRB1*1501 allele of the HLA-DR15 hap-
lotype, the previously reported susceptibility to PLP91-
110 epitope was associated with the DRB1*0301, a
non-Caucasian MS-associated allelic gene of the HLA-
DR3 haplotype. Our results show that, unlike the pre-
viously reported HLA-DR-dependent susceptibility to
MBP-, PLP-, or MOG-induced EAE, the pathogenic
autoimmunity against PLP, as well as against MOBP
[28], was dependent on HLA-DQB1*0602 rather than
HLA-DRB1*1501. This DQB1*0602-associated suscept-
ibility is in striking contrast with human and trans-
genic mouse studies suggesting a protective role for
HLA-DQ6. The closely related allele DQB1*0601, most
typically found in South Asian populations, has been
reported in two human studies to be associated with
protection from MS [31,46]. In accordance with those
findings, studies in HLA-Tg-mice [29,30] argued that
the presence of HLA-DQB1*0601 could exert an epi-
static protective effect on HLA-DR-dependent, anti-
myelin autoimmunity. Thus, while HLA-DRB1*1502
Tg mice were susceptible to MOG-induced EAE, the
HLA(DRB1*1502 × DQB1*0601) double-Tg mice were
resistant [29]. The protective effect of HLA-DQ6
(DQA1*0103/DQB1*0601) was reported in more detail
in PLP-induced EAE, in which HLA-DR3(DRB1*0301)-
Tg mice were susceptible to PLP91-110-induced dis-
ease, whereas the HLA-DR3(DRB1*0301) × DQ6
(DQB1*0601) double-Tg mice were protected [30]. In
our studies, using the Caucasian MS-associated allelic
genes (of the HLA-DR15 haplotype) we show the
opposite scenario for the role of the HLA-DQ6 in anti-
myelin autoimmunity in HLA-Tg mice, as the HLA-
DQB1*0602 gene product determined susceptibility to
PLP- as well as to MOBP-induced EAE.
The PLP-induced EAE in HLA-DQB1*0602 transgenic
mice showed a typical caudo-rostral clinical progression
that was associated with CNS demyelination, axonal
damage and with optic neuritis. However, unlike usually
observed in PLP-induced disease or other EAE models
in the wild type mice, the CNS pathology in phPLP175-
194-induced EAE in HLA-DQB1*0602 transgenics was
more pronounced in the brain rather than in the spinal
cord. Such a strong involvement of cerebellum and
brainstem exceeding that of spinal cord, which has been
suggested by Stromnes et al. [42] to be a feature of
T h 1 7 - d r i v e nd i s e a s e ,c o r r e s p o n d e dt ot h eh i g hT h 1 7
secretion by PLP175-194-primed LNC derived from
DQB1*0602-Tg mice. It should be noted that the
DRB1*1501-Tg line (originated from C. David and main-
tained in our animal facility as homozygotic line for sev-
eral years) which is refractory to PLP139-151- and to
PLP175-194-induced EAE, or to MOBP15-36- induced
EAE [28], is susceptible in our hands to EAE induced by
MOG35-55 and to MBP89-104 (data not shown), indi-
cating that the disease-resistance or -susceptibility is the
result of a selective DRB1*1501-associated Th2 autoim-
munity, and DQB1*0602-associated Th1/Th17 autoim-
munity, against PLP and MOBP in the setting of the
these HLA-humanized mice. Whether such a selective
preference for Th2 autoimmunity against PLP or MOBP
in the context of DRB1*1501, and Th1/Th17 autoimmu-
nity in the context of DQB1*0602, occurs also in HLA-
D R 1 5 +M Ss h o u l db ee x a m i n e db ye x - v i v oa n a l y s i st h e
patients’ responses to these myelin antigen/epitopes in
the context of DRB1*1501- and DQB1*0602-associated
antigen presentation.
Over the last three decades, autoimmunity against
MBP, PLP, and more recently also against other CNS
myelin proteins, such as MOG, MOBP and OSP, has
been extensively investigated in MS patients, HLA
class-II Tg mice, and in wild-type mice, as major target
antigens in MS. Clearly we do not yet know the full
extent of CNS proteins that may become autoimmune
targets in MS, but the credentials of PLP as a target,
both in human MS and mouse models are very com-
pelling. When comparing PLP and MBP, PLP is stron-
ger and dominant encephalitogen at least in some EAE
models, particularly in SJL/J mice where PLP139-151
and PLP175-194 are the co-dominant encephalitogenic
PLP epitopes [43]. TCR
PLP transgenic mice on the SJL/
J background develop spontaneous EAE with a rela-
tively high frequency [47] compared with TCR
MBP
transgenic mice on B10.PL background [48]. Further,
upon EAE induction with whole spinal cord homoge-
nate, the dominant T cell response is directed against
PLP139-151 [49]. These PLP encephalitogenic peptides
are also seen in MS patients’ responses. A study on
high avidity myelin specific T cells in MS documented
that both PLP139-151 and the PLP178-191 epitopes
are key targets of high avidity T-cell allels and clearly
elevated in MS versus healthy controls [50]. Perhaps
most tellingly, a clinical/MRI relapse triggered in a
patient as consequence of an altered peptide ligand
(APL) clinical trial was temporally correlated with
spread of their response to PLP 190-209 [51]. Hence,
the potential contribution of the autoimmunity against
PLP to the pathogenesis of MS, which is likely to be
Kaushansky et al. Journal of Neuroinflammation 2012, 9:29
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quite significant.
Conclusions
Overall, our results showing that DQB1*0602 but not
DRB1*1501 determines pathogenic autoimmunity
against PLP as well as against MOBP [28] in the HLA-
Tg mice suggest a differential, functional role for
DQB1*0602 as a predisposing allele in MS, to a greater
extent than previously perceived. This places MS more
firmly in the group of autoimmune diseases in which a
functional association is presumed, including type I dia-
betes and celiac disease [52,53]. The findings showing
that DQB1*0602 determines pathogenic autoimmunity
against PLP and MOBP [28], together with previously
reported studies showing that DRB1*1501 determines
pathogenic autoimmunity against MBP and MOG
[24,27] suggest a more complex and differential genetic
predisposition to HLA-DR15+ MS, depending on the
primary CNS target antigen/epitope against which the
pathogenic autoimmunity is primarily directed, or trig-
gered (genotype/antigen/phenotype relationship). Thus,
in view of the complex anti-CNS autoimmunity asso-
ciated with MS and the divergent patterns of clinical
manifestation of MS, further work using complementary
studies of reductionist transgenic models with the more
complex analysis of patient responses will be necessary
to elucidate these patterns and potential ‘genotype/target
Ag(epitope)/phenotype’ relationship. This is essential for
devising immune-specific therapy as well as for gaining
n e wi n s i g h t si n t ot h ee t i o l o g yo fM S .I ti sa l s oo f
immense significance for many other areas of endeavor
in MS research, from analysis and immune-specific tar-
geting of pathogenic TCR [54] to peptide immunothera-
pies [55] and programs tracking patient responses [56]
for more effective treatment protocols.
Additional material
Additional file 1: Figure S1. Epitope-specificity of hΔPLP -primed T-cells
derived from DRB1*1501- and DQB1*0602-Tg mice: Ex-vivo recall
proliferative response to overlapping human PLP peptides. HLA-
DRB1*1501- and DQB1*0602- Tg mice (two mice per Tg line) were
immunized (s.c.) in the flank with 200 μgo fh ΔPLP in CFA for induction
of EAE (as described in Methods, protocol 2). Spleen cells were obtained
on day 14 after immunization and cultured in vitro in triplicates in the
absence or presence of 1 or 2.5 μg/ml of each of the overlapping
peptides for the ex-vivo analysis of the recall proliferative response to a
panel of overlapping peptides spanning the hydrophilic domains of
native hPLP. The hydrophilic domains of native hPLP correspond to the
hΔPLP, except that in the hΔPLP some of the Cys of the native PLP were
replaced by Ser (see Figure 1) to increase solubility. Results are the mean
S.I. of two individual spleens from mice immunized with same peptide in
each HLA-Tg line. *, and **, represent native PLP peptides, the cysteines
of which were replaced by serine in the hΔPLP, where *, depicts
peptides containing Cys within the nonameric core epitope for
DRB1*1501 and/or DQB1*0602 molecule, but is not a major TCR or MHC
binding residue, as predicted in silico: and **, depicts peptides
containing Cys in the nonameric core epitope for DRB1*1501 and/or
DQB1*0602 molecule that was predicted in silico to be a major TCR-
contact or MHC-contact residue.
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